Tag: xarelto
Real-world analysis confirms benefit of Xarelto in treating CAT as apixaban
Head-to-head observational analysis showed Xarelto as effective in treating cancer-associated thromboembolism (CAT) as apixaban.
The Janssen Pharmaceutical Companies of Johnson & Johnson have announced observational...
FDA approves two paediatric venous thromboembolism indications for Janssen’s Xarelto
The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced that the US Food and Drug Administration (FDA) has approved two paediatric indications for...
Janssen submits new drug application to US FDA for Xarelto (rivaroxaban)...
The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced it has submitted a new drug application (NDA) to the US Food and Drug...
Bayer receives approval in the UK for Xarelto to treat and...
Bayer has received approval in the UK for the use of its oral Factor Xa inhibitor Xarelto (rivaroxaban) to treat venous thromboembolism (VTE) and...
Rivaroxaban associated with reduced risk of recurrent VTE versus warfarin in...
In a study evaluating rivaroxaban (Xarelto; Bayer) versus warfarin for the treatment and prevention of recurrent venous thromboembolism (VTE) in patients with obesity, results...
New research reveals decreased risk of recurrent VTE in morbidly obese...
The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the publication of new real-world evidence which confirms that XARELTO (rivaroxaban) reduces the risk...
FDA mini-sentinel assessment confirms safety and effectiveness of Xarelto (rivaroxaban) amidst...
The Janssen Pharmaceutical Companies of Johnson & Johnson has announced findings from the US Food and Drug Administration's (FDA) mini-sentinel assessment, confirming the positive...
FDA approves new 10mg dosing for rivaroxaban to reduce continued risk...
Janssen Pharmaceuticals has announced that the FDA has approved the 10mg once-daily dose of rivaroxaban (Xarelto) for reducing the continued risk for recurrent venous...
FDA grants priority review of Xarelto for a 10mg dose to...
The US Food and Drug Administration (FDA) has accepted, for priority review, a supplemental new drug application (sNDA) for Janssen’s Xarelto (rivaroxaban), to include...
Two new real-world studies confirm positive efficacy and safety profile of...
Janssen Pharmaceuticals and its development partner, Bayer, announced on 23 October 2016 results of two new real-world studies confirming the positive benefit-risk profile of...